OPEN MONOCLONAL TECHNOLOGY, INC.;WuXi Biologics Ireland Limited
发明人:
Jieying LIU,Jing LI
申请号：
US16334767
公开号：
US20190233542A1
申请日:
2017.09.12
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present disclosure provides monoclonal antibodies against Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), which can block the binding of PCSK9 to LDL receptor, and therefore lower the level LDL-C. The antibodies of disclosure provide very potent agents for the treatment of multiple CVDs.
